Human pathology
High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy.
Carlotta Franzina, Michele Bevere, Samantha Bersani, Paola Mattiolo, Carlotta Ceccon, Paola Piccoli, Giuseppe Malleo, Rita T Lawlor, Roberto Salvia, Michele Milella, Matteo Fassan, Aldo Scarpa, Claudio Luchini
Published: 202510.1016/j.humpath.2025.106014
Abstract
Claudin-18.2 (CLDN18.2) is a tight-junction protein that can be expressed in various neoplasms, including pancreatic ductal adenocarcinoma (PDAC). Anti-CLDN18.2 targeted therapies have already been approved for CLDN18.2-positive gastric cancer and ar…
Preview only. Read the full abstract at the source